Limits...
Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer.

Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, Ichikawa T, Seki N - Cancer Sci. (2014)

Bottom Line: Our recent studies of the microRNA (miRNA) expression signature in prostate cancer (PCa) indicated that miRNA-218 (miR-218) was significantly downregulated in clinical specimens, suggesting that miR-218 might act as a tumor-suppressive miRNA in PCa.LASP1 is a cytoskeletal scaffold protein that plays critical roles in cytoskeletal organization and cell migration.Our data on pathways regulated by tumor-suppressive miR-218 provide new insight into the potential mechanisms of PCa oncogenesis and metastasis.

View Article: PubMed Central - PubMed

Affiliation: Department of Functional Genomics, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

Show MeSH

Related in: MedlinePlus

Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM miR-218, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. *P < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317931&req=5

fig02: Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM miR-218, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. *P < 0.001.

Mentions: The XTT assay demonstrated that cell proliferation was not inhibited in miR-218 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 2a).


Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer.

Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, Ichikawa T, Seki N - Cancer Sci. (2014)

Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM miR-218, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. *P < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317931&req=5

fig02: Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM miR-218, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. *P < 0.001.
Mentions: The XTT assay demonstrated that cell proliferation was not inhibited in miR-218 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 2a).

Bottom Line: Our recent studies of the microRNA (miRNA) expression signature in prostate cancer (PCa) indicated that miRNA-218 (miR-218) was significantly downregulated in clinical specimens, suggesting that miR-218 might act as a tumor-suppressive miRNA in PCa.LASP1 is a cytoskeletal scaffold protein that plays critical roles in cytoskeletal organization and cell migration.Our data on pathways regulated by tumor-suppressive miR-218 provide new insight into the potential mechanisms of PCa oncogenesis and metastasis.

View Article: PubMed Central - PubMed

Affiliation: Department of Functional Genomics, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

Show MeSH
Related in: MedlinePlus